Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Untangling DNA Regulation

By Drug Discovery Trends Editor | November 10, 2008

MIT biologists have discovered that the organization of DNA’s packing material plays a critical role in directing stem cells to become different types of adult cells.

The work, to be published in the journal Cell on Nov. 14, could also shed light on the possible role of DNA packaging in cancer development.

Led by Laurie Boyer, assistant professor of biology at MIT, the researchers examined the role of chromatin — the structure that forms when DNA is wound around a core of proteins called histones.

‘We’re particularly interested in how chromatin structure influences gene expression and ultimately cell fate,’ Boyer said. ‘We hope the studies we are doing can lead to better understanding of development as well as certain diseases.’

It has been theorized that cancer cells may overexpress genes involved in early embryonic development, allowing them to proliferate unchecked and regress from adult tissue cells to a stem cell-like state.

Such regression could be partly mediated by changes in chromatin. This packaging is believed to help control DNA transcription because the more tightly wound the chromatin is, the less accessible DNA is to be transcribed.

The new study focused on a variant type of histone known as H2AZ, which other researchers have recently identified as a protein of interest in cancer.

While H2AZ is ubiquitously expressed in many cell types including adult cells, it is known to be essential for normal embryonic development. The new research reveals why: The variant histones are found near the promoter regions of a particular set of genes that are important for development.

The same genes are also regulated by a group of proteins known as Polycomb group (PcG) proteins, which act as gene silencers.

‘It suggests that this histone variant — along with the Polycomb group proteins — may act as some kind of regulatory switch that mediates cell fate transitions,’ Boyer said. ‘We hypothesize that they’re working together, and that allows these genes to be silent yet poised for activation in stem cells.’

In future studies, Boyer’s team plans to look at patterns of H2AZ distribution in cancerous cells.

Release Date: November 6, 2008
Source: Massachusetts Institute of Technology 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50